# Axcelead > Drug Discovery Partners ## Pages - [Thank you inquiry HTS](https://axcelead-us.com/thank-you-inquiry-hts/): Contact Us Thank you for your inquiry. Thank you for your inquiry. Our team will contact you within 3-4 working... - [High Throughput Screening, DEL & AI-Powered Hit Discovery Services](https://axcelead-us.com/high-throughput-screening/): Technology Platforms High Throughput Screening, DEL & AI-Powered Hit Discovery Services Accelerate hit discovery through integrated high-throughput screening (HTS) and... - [Test Gateway](https://axcelead-us.com/events/test-gateway/): Events Seminars - [Webinar Gateway](https://axcelead-us.com/webinar-gateway/): Seminars Your Content Goes Here - [In Vitro/In Vivo Pharmacology](https://axcelead-us.com/in-vitro-in-vivo-pharmacology/): Technology Platforms In Vitro / In Vivo Pharmacology Disease-Relevant Pharmacology to Strengthen Translational Confidence Axcelead provides integrated in vitro and... - [Axcelead Booster](https://axcelead-us.com/integrated-drug-discovery/axcelead-booster/): Integrated Drug Discovery Axcelead Booster Accelerating Drug Candidate Generation With Our Pharma-originated Discovery Platform What is Axcelead Booster (A-Booster)? —... - [Home](https://axcelead-us.com/): The Future of Drug Discovery is Here. Axcelead accelerates the discovery and development of high-value therapeutic candidates for the preclinical... - [Genetically Modified Animal](https://axcelead-us.com/genetically-modified-animal/): Technology Platforms Genetically Modified Animal Comprehensive Solutions for Genetically Modified Animals Genetically modified animal models are useful tools in translational... - [Bioinformatics](https://axcelead-us.com/bioinformatics/): Technology Platforms Bioinformatics Bioinformatics Solutions to Accelerate Drug Discovery Turning Omics Data into Actionable Insights Our bioinformatics solutions help accelerate... - [Topics](https://axcelead-us.com/topics/): News Topics 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 - [News Releases](https://axcelead-us.com/news-releases/): News News Releases 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 - [Omics](https://axcelead-us.com/omics/): Technology Platforms Omics Multiple Omics Platform for Precision Drug Discovery Driving Translational Research and Innovation in Drug Discovery Our advanced... - [Small Molecules](https://axcelead-us.com/small-molecules/): Therapeutic Modalities Small Molecules Small Molecule Drugs: The Cornerstone of Future Pharmaceutical Innovation Small molecule drugs have been the dominant... - [Chemistry](https://axcelead-us.com/chemistry/): Axcelead Chemistry services are designed to help you create the medicines of the future. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive chemistry solutions can help you achieve your scientific goals more efficiently. - [Targeted Protein Degraders](https://axcelead-us.com/targeted-protein-degraders/): Therapeutic Modalities Targeted Protein Degradation Axcelead Holistic Solution for Targeted Protein Degradation (TPD) Drug Discovery Axcelead has comprehensive capabilities in... - [RNA-Targeted Small Molecules](https://axcelead-us.com/rna-targeted-small-molecules/): Therapeutic Modalities RNA-Targeted Small Molecules Axcelead Holistic Solution for RNA-targeted Small Molecule Axcelead has comprehensive capabilities in integrated RNA-targeted small... - [Peptide](https://axcelead-us.com/peptide/): Therapeutic Modalities Peptide Our Approach to Overcoming Challenges in Peptide Drug Discovery PHN0eWxlPgouc3RyZW5ndGgtd2hpdGV3cmFwIHsKICBoZWlnaHQ6IDI3MHB4Owp9Ci5ub3JtYWwtd2VpZ2h0IHsKIAlmb250LXdlaWdodDogNDAwIWltcG9ydGFudDsgCn0KLmlzc3Vlcy1saXN0IHsKICAgbGlzdC1zdHlsZTogbm9uZTsKICAgbWFyZ2luOiAwOwogICBwYWRkaW5nOiAwOyAKfQouaXNzdWVzLWxpc3QgbGkgewogICB0ZXh0LWFsaWduOiBjZW50ZXI7CiAgIHBhZGRpbmc6IDE1cHg7CiAgYm9yZGVyLWJvdHRvbTogMXB4IHNvbGlkICNmZmY7Cn0KLmlzc3Vlcy1saXN0IGxpOmxhc3Qtb2YtdHlwZSB7CiAgYm9yZGVyLWJvdHRvbTogMXB4IHNvbGlkIHRyYW5zcGFyZW50Owp9CkBtZWRpYSBvbmx5IHNjcmVlbiBhbmQgKG1heC13aWR0aDogNjAwcHgpewogIC5zdHJlbmd0aC13aGl0ZXdyYXAgewogICAgaGVpZ2h0OiBhdXRvOwogIH0KfQo8L3N0eWxlPg== A Comprehensive One-Stop Solution for All Your... - [Oligonucleotide](https://axcelead-us.com/oligonucleotide/): Therapeutic Modalities Oligonucleotide Your Partner in Oligonucleotide Drug Discovery Safety and delivery are the main challenges associated with discovering and... - [Cardiovascular / Metabolic disease](https://axcelead-us.com/therapeutic-areas/cardiovascular-metabolic-disease/): Therapeutic Areas Cardiovascular / Metabolic Disease At Axcelead, we have extensive experience and know-how in the preclinical development of new... - [Thank you inquiry](https://axcelead-us.com/thank-you-inquiry/): Contact Us For questions and consultations about our business and services, please use the form below. Thank you for your... - [Previous Conferences](https://axcelead-us.com/events/previous-conferences/): Welcome to view the conferences that Axcelead Drug Discovery Partners, Inc. has attended. - [IND-enabling](https://axcelead-us.com/integrated-drug-discovery/ind-enabling/): Integrated Drug Discovery Offering End-to-End Solutions IND Enabling Smart-IND Our proprietary process is designed to accelerate the development project time... - [Neuroscience](https://axcelead-us.com/therapeutic-areas/neuroscience/): Therapeutic Areas Advancing Neuroscience Research We understand that developing drugs for neuroscience indications can be challenging. We utilize an integrated... - [Immunology](https://axcelead-us.com/therapeutic-areas/immunology/): Therapeutic Areas Advancing Immunology Research We can design and carry out the most appropriate in vitro and/or in vivo studies... - [Oncology](https://axcelead-us.com/therapeutic-areas/oncology/): Therapeutic Areas Advancing Oncology Research We have a long and proven track record in the development of small molecules for... - [Future Conferences](https://axcelead-us.com/events/conferences/): Welcome to view the conferences that Axcelead Drug Discovery Partners, Inc. will be attending. - [Previous Seminars](https://axcelead-us.com/events/previous-seminars/): Welcome to view the seminars that Axcelead Drug Discovery Partners, Inc. has held. - [Future Seminars](https://axcelead-us.com/events/seminars/): Welcome to view the seminars that Axcelead Drug Discovery Partners, Inc. will be holding. - [Candidate Selection](https://axcelead-us.com/integrated-drug-discovery/candidate-selection/): Integrated Drug Discovery Offering End-to-End Solutions Candidate Selection Candidate Selection is vital in drug discovery as in which, the optimized... - [Lead Generation / Optimization](https://axcelead-us.com/integrated-drug-discovery/lead-generation-optimization/): Integrated Drug Discovery Offering End-to-End Solutions Lead Generation / Optimization Axcelead has all must-have functions for efficient lead generation and... - [Hit Identification / Characterization](https://axcelead-us.com/integrated-drug-discovery/hit-identification-characterization/): Integrated Drug Discovery Offering End-to-End Solutions Hit Identification / Characterization Axcelead will design a robust HTS strategy, starting from assay... - [Integrated Drug Discovery](https://axcelead-us.com/integrated-drug-discovery/): Axcelead offers integrated drug discovery and development solutions to clients worldwide, including academia, biotechnology, and pharmaceutical companies. Our experienced team works closely with you at every step of your drug discovery project, from target identification, hit identification and characterization, lead generation and optimization, and candidate selection to IND enabling and beyond. - [Target Identification / Validation](https://axcelead-us.com/integrated-drug-discovery/target-identification-validation/): Integrated Drug Discovery Offering End-to-End Solutions Target Identification / Validation Target Identification would have a significant impact in drug discovery... - [Contact Us](https://axcelead-us.com/contact-us/): Contact Us For questions and consultations about our business and services, please use the form below. PGlmcmFtZSBzcmM9Imh0dHBzOi8vZ28uYXhjZWxlYWQuY29tL2wvOTk2MjYxLzIwMjYtMDQtMDYvYmoyZGMiIHdpZHRoPSIxMDAlIiBoZWlnaHQ9IjE1NTAiIHR5cGU9InRleHQvaHRtbCIgZnJhbWVib3JkZXI9IjAiIGFsbG93VHJhbnNwYXJlbmN5PSJ0cnVlIiBzdHlsZT0iYm9yZGVyOiAwIj48L2lmcmFtZT4= Contact Us Please... - [Brochures](https://axcelead-us.com/resources/brochures/): Company Introduction 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 Integrated Drug Discovery 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 Therapeutic Areas 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 Technology Platforms 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 Therapeutic Modalities 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 - [Publications](https://axcelead-us.com/resources/publications/): Publications 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 - [Presentations](https://axcelead-us.com/resources/presentations/): Presentations PHNjcmlwdD4Kc2V0VGltZW91dChmdW5jdGlvbigpIHsKICBqUXVlcnkoZG9jdW1lbnQpLnJlYWR5KGZ1bmN0aW9uKCQpIHsgCgkkKCIuZnVzaW9uLXZlcnRpY2FsLW1lbnUtd2lkZ2V0IHVsIGxpIikuZWFjaChmdW5jdGlvbigpewoJCWxpbmtBbm51YWwgPSAkKCJhIiwgJCh0aGlzKSk7IAogICAgICAgIG9yaWdpbmFsSHJlZiA9ICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIpOwogICAgICAgICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIsIG9yaWdpbmFsSHJlZiArICI/Y2F0PTE4Iik7IC8vIFByZXNlbnRhdGlvbiBjYXRlZ29yeQogICAgfSk7CiAgfSk7Cn0sIDgwMCk7Cjwvc2NyaXB0Pg== - [Videos](https://axcelead-us.com/resources/videos/): Resources Explore our library of capabilities Toggle NavigationVideosPresentationsPublicationsPostersBrochures Hot Topics Move your hits to candidates faster with AxceleadAxcelead delivers quality... - [Posters](https://axcelead-us.com/resources/posters/): Posters PHNjcmlwdD4Kc2V0VGltZW91dChmdW5jdGlvbigpIHsKICBqUXVlcnkoZG9jdW1lbnQpLnJlYWR5KGZ1bmN0aW9uKCQpIHsgCgkkKCIuZnVzaW9uLXZlcnRpY2FsLW1lbnUtd2lkZ2V0IHVsIGxpIikuZWFjaChmdW5jdGlvbigpewoJCWxpbmtBbm51YWwgPSAkKCJhIiwgJCh0aGlzKSk7IAogICAgICAgIG9yaWdpbmFsSHJlZiA9ICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIpOwogICAgICAgICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIsIG9yaWdpbmFsSHJlZiArICI/Y2F0PTE5Iik7IC8vIFByZXNlbnRhdGlvbiBjYXRlZ29yeQogICAgfSk7CiAgfSk7Cn0sIDUwMCk7Cjwvc2NyaXB0Pg== - [News](https://axcelead-us.com/news/): News Latest News and Press Releases 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 - [Test Page with Mega Menu](https://axcelead-us.com/test-page-with-mega-menu/): The Future of Drug Discovery is Here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt... - [Cookie Policy](https://axcelead-us.com/cookie-policy/): Policies Cookie Policy2021/05/27 About Cookies Cookies are data stored directly on your computer. They are used to gather information such... - [Privacy Policy: Personal Information Protection Policy](https://axcelead-us.com/privacy-policy-personal-information-protection-policy/): Policies Privacy Policy: Personal Information Protection Policy １． Policy Axcelead Drug Discovery Partners Inc. (the “Company”), in order to appropriately... - [About Us](https://axcelead-us.com/about-us/): About Us We are pioneering the future of drug discovery. https://axcelead-us. com/wp-content/uploads/2023/12/whoweare-topimage2. jpg Who We Are Axcelead is your trusted... - [Privacy Policy](https://axcelead-us.com/privacy-policy/): Policies Privacy Policy Axcelead Group has established a basic policy for the handling of personal information, and will comply with... ## Posts - [Overcoming “No Hit” and Hit Expansion Bottlenecks: An Integrated HTS, AI, and DEL Approach for Difficult-to-Drug Targets](https://axcelead-us.com/future-seminars/webinar_20261015/): Early-stage drug discovery is often hindered by two major challenges. The first is identifying initial hits against difficult-to-drug targets. The... - [Elix and Axcelead DDP Enter into Collaborative Research Agreement to Advance Targeted Protein Degrader Discovery: Combining AI Drug Discovery Technologies with Drug Discovery Expertise to Advance Solutions for Challenging Targets](https://axcelead-us.com/news/elix-and-addp-enter-into-collaborative-research-agreement/): News 2026. 09. 09 Tokyo and Fujisawa, Japan, September 9, 2026 – Elix, Inc. (Headquarters: Chiyoda-ku, Tokyo; hereinafter “Elix”) and... - [A Deep Dive into the FDA NAMs Road Map with Former Senior Management of the FDA](https://axcelead-us.com/previous-seminars/fda-nams-road-map/): NAMs Road Map was published in April 2025. The goal in non-clinical safety studies is to transition from animal studies... - [LSX USA Congress 2026](https://axcelead-us.com/future-conferences/lsx-usa-congress-2026/): Boston, MA - [Emi Matsumoto from Translational Research Business Unit to present a poster at Safety Pharmacology Society 2026 Annual Meeting](https://axcelead-us.com/topics/poster-presentation-at-safety-pharmacology-society-2026/): Topics Emi Matsumoto from Translational Research Business Unit to present a poster at Safety Pharmacology Society 2026 Annual Meeting 2026.... - [Job Shadowing Program for High School Students](https://axcelead-us.com/topics/job-shadowing-program/): Topics 2026. 08. 25 On August 19, 2026, we hosted a job shadowing program for two high school students. Job... - [Proteomic Analysis for Off-Target Risk Assessment of Targeted Protein Degraders](https://axcelead-us.com/posters/proteomic-analysis-for-off-target-risk-assessment-of-targeted-protein-degraders/): The 53rd Annual Meeting of the Japanese Society of Toxicology (JSOT 2026) Download - [Predicting Drug-Induced Liver Injury Using Machine Learning: A Novel Approach Integrating Multiple In Vitro Assays](https://axcelead-us.com/posters/predicting-drug-induced-liver-injury-using-machine-learning-a-novel-approach-integrating-multiple-in-vitro-assays-2/): The 53rd Annual Meeting of the Japanese Society of Toxicology (JSOT 2026) Download - [Cytokine release assay using human PBMCs enables CRS risk stratification of therapeutic antibodies](https://axcelead-us.com/posters/cytokine-release-assay-using-human-pbmcs-enables-crs-risk-stratification-of-therapeutic-antibodies/): The 53rd Annual Meeting of the Japanese Society of Toxicology (JSOT 2026) Download - [Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand-Based Virtual Screening Approaches](https://doi.org/10.1002/cmdc.70362#new_tab): ChemMedChem - [Paper on AI-Driven Discovery of Novel Chemical Scaffolds Published in ChemMedChem](https://axcelead-us.com/topics/publication-in-chemmedchem/): Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand-Based Virtual Screening Approaches Publication Published Date: 08 July 2026... - [Improving Translational Decision-Making in Obesity and CKD with In Vivo Phenotyping and Clinically Relevant Models](https://axcelead-us.com/future-seminars/webinar_20260910/): Translational risk remains a major challenge in obesity and kidney disease drug development, often leading to uncertainty in preclinical decision-making.... - [Improving Translational Decision-Making in Oncology and Immunology with Human-Relevant Models and Immune Profiling](https://axcelead-us.com/previous-seminars/webinar_20260825/): Translational risk remains a major challenge in oncology and immunology drug discovery. In oncology, the complexity of the tumor microenvironment... - [Notice Regarding Unauthorized Access to an Employee Email Account](https://axcelead-us.com/news/notice-regarding-unauthorized-access-to-an-employee-email-account/): Fujisawa, Japan – July 22, 2026 – We have confirmed that a third party gained unauthorized access to an employee... - [Pharmacological and Toxicological Profiling and Efficacy Predictability of an Antisense Oligonucleotide Following Repeated Intrathecal Administration](https://axcelead-us.com/posters/pharmacological-and-toxicological-profiling-and-efficacy-predictability-of-an-antisense-oligonucleotide-following-repeated-intrathecal-administration/): The 11th Annual Meeting of Nucleic Acids Therapeutics Society of Japan Download - [A paper describing the drug discovery research of the CDK12 inhibitor CTX-439 has been published in ACS Medicinal Chemistry Letters](https://axcelead-us.com/topics/publication_acs-medicinal-chemistry-letters/): Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug Publication Published Date: 2026/6/23 The results... - [Dr. Takakuwa from Translational Research Business Unit to present a poster at the 11th Annual Meeting of Nucleic Acids Therapeutics Society of Japan](https://axcelead-us.com/topics/dr-takakuwa-presentation-11th-natsj/): Dr. Takakuwa, a researcher from the Translational Research Business Unit, will have a poster presentation at the 11th Annual Meeting... - [Route-Dependent Central Effects and Efficacy Prediction of a Nucleic Acid Drug: Comparison of ICV and IT Administration](https://axcelead-us.com/posters/route-dependent-central-effects-and-efficacy-prediction-of-a-nucleic-acid-drug-comparison-of-icv-and-it-administration/): The 99th Annual Meeting of the Japanese Pharmacological Society Download - [Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug](https://pubs.acs.org/doi/10.1021/acsmedchemlett.6c00138): ACS Medicinal Chemistry Letters - [Researcher Yuka Hasegawa from the Translational Research Business Unit to present a poster at the 53rd Annual Meeting of the Japanese Society of Toxicology](https://axcelead-us.com/topics/hasegawa-present-poster-53rd-jsot/): Yuka Hasegawa, a researcher from the Translational Research Business Unit, will have an oral and a poster presentation at the... - [Gateway - Maximizing Human Predictability from In Vivo Pharmacology Studies](https://axcelead-us.com/test/maximizing-human-predictability-from-in-vivo-pharmacology-studies-2/): Join this webinar to find out how we can help accelerate your Drug Discovery! our first speaker will provide an... - [Dr. Qinge Liang, a researcher from the Translational Research Business Unit, will have an oral and a poster presentation at the 53rd Annual Meeting of the Japanese Society of Toxicology](https://axcelead-us.com/topics/dr-liang-presentation-53rd-jsot/): Dr. Qinge Liang, a researcher from the Translational Research Business Unit, will have an oral and a poster presentation at... - [Axcelead DDP Joins Lilly TuneLab to Advance AI Drug Discovery](https://axcelead-us.com/news/addp-joins-lilly-tunelab/): Fujisawa, Japan, June 18, 2026 — Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) is pleased to announce that it has... - [Researcher Furukawa from the Discovery Technologies Business Unit to present a poster at the 53rd Annual Meeting of the Japanese Society of Toxicology (JSOT)](https://axcelead-us.com/topics/furukawa-present-poster-53rd-jsot/): Researcher Furukawa from the Discovery Technologies Business Unit to present a poster at the 53rd Annual Meeting of the Japanese... - [Enhancing Clinical Predictability through Human Disease-relevant Preclinical Models in CNS and Muscle Drug Discovery](https://axcelead-us.com/previous-seminars/webinar-cns-muscle_20260722/): Drug discovery for central nervous system (CNS) and muscle diseases continues to face major translational challenges. Conventional models often fail... - [Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping](https://axcelead-us.com/previous-seminars/improving-preclinical-decision-making-in-obesity-and-ckd-with-translational-in-vivo-phenotyping/): Join this webinar to find out how we can help you identify promising novel leads! In this webinar, we will... - [BIO International Convention 2026](https://axcelead-us.com/previous-conferences/bio-international-convention-2026/): Boston, MA - [J-Pharma’s LAT1 Inhibitor JPH034 Initiates Phase 1 Clinical Trial in the United States – Axcelead DDP Supported Multiple IND-Enabling Studies –](https://axcelead-us.com/topics/j-pharmas-phase-1-clinical-trial-in-us/): J-Pharma Co. , Ltd. (“J-Pharma”) has announced that dosing of the first subject has commenced in the Phase 1 clinical... - [Irbesartan but not Roflumilast Ameliorates Renal Injury in a Col4a5 R471* Mutant Mouse Model of Alport Syndrome and CKD](https://axcelead-us.com/posters/irbesartan-but-not-roflumilast-ameliorates-renal-injury-in-a-col4a5-r471-mutant-mouse-model-of-alport-syndrome-and-ckd/): The World Congress of Nephrology 2026 Download - [Inducible Exon Skipping After Disease Onset as a Therapeutic Strategy for CKD：Evaluation in a Patient-Derived Mouse Model of Alport Syndrome](https://axcelead-us.com/posters/inducible-exon-skipping-after-disease-onset-as-a-therapeutic-strategy-for-ckd%ef%bc%9aevaluation-in-a-patient-derived-mouse-model-of-alport-syndrome/): The World Congress of Nephrology 2026 Download - [Co-authored Paper by Researcher Matsumoto and Researcher Miura of the Translational Research Business Unit Published in Gut Pathogens](https://axcelead-us.com/topics/co-authored-paper-published-in-gut-pathogens/): Cross-organ multi-omics profiling of microbiome and metabolome along the gut-liver axis in MASH model mice induced by western diet and... - [Cross-organ multi-omics profiling of microbiome and metabolome along the gut-liver axis in MASH model mice induced by western diet and MC4R knockout](https://www.mdpi.com/2218-1989/16/2/113): Gut Pathogens - [Drug Discovery Services for Rare Disease](https://axcelead-us.com/brochures/drug-discovery-services-for-rare-disease/): Download - [Researcher Yamamoto from Pharmacology Business Unit to Present a Poster at the World Congress of Nephrology 2026](https://axcelead-us.com/topics/yamamoto-present-poster-wcn2026/): Researcher Yamamoto from Pharmacology Business Unit, will deliver a poster presentation at The World Congress of Nephrology 2026, to be... - [Researcher Hashikami from Pharmacology Business Unit to Present a Poster at the World Congress of Nephrology 2026](https://axcelead-us.com/topics/hashikami-present-poster-wcn2026/): Researcher Hashikami from Pharmacology Business Unit , will deliver a poster presentation at The World Congress of Nephrology 2026, to... - [Proteros and Axcelead DDP Enter Strategic Collaboration to Enhance Discovery Capabilities](https://axcelead-us.com/news/proteros-addp-strategic-collaboration/): Proteros and Axcelead DDP Enter Strategic Collaboration to Enhance Discovery Capabilities Axcelead gains access to Proteros’ capabilities in structural biology... - [Investigation of storage conditions and quality control markers for metabolites and lipids in human feces](https://www.mdpi.com/2218-1989/16/2/113): Metabolites - [A co-authored paper by researcher Miura of the DMPK & Safety Business Unit was published in Metabolites](https://axcelead-us.com/topics/miura-publication-metabolites/): Investigation of storage conditions and quality control markers for metabolites and lipids in human feces Publication Published Date: February 4,... - [Dr. Hirano from Screening Business Unit will give an oral presentation at the symposium of the 99th Annual Meeting of the Japanese Pharmacological Society](https://axcelead-us.com/topics/hirano-present-99th-jps/): Dr. Hirano from the Screening Business Unit, will deliver an oral presentation at The 99th Annual Meeting of the Japanese... - [Researcher Hitaka of the Pharmacology Business Unit will present a poster at the 99th Annual Meeting of the Japanese Pharmacological Society](https://axcelead-us.com/topics/hitaka-poster-99th-jps/): Researcher Hitaka from the Pharmacology Business Unit, will deliver a poster presentation at The 99th Annual Meeting of the Japanese... - [Dr. Murakami from Pharmacology BU to present at the symposium of the 99th Annual Meeting of the Japanese Pharmacological Society](https://axcelead-us.com/topics/murakami-symposium-99th-jps/): Dr. Murakami from the Pharmacology Business Unit, will deliver an oral presentation at The 99th Annual Meeting of the Japanese... - [Dr. Takakuwa from Pharmacology Business Unit to present a poster at the 99th Annual Meeting of the Japanese Pharmacological Society](https://axcelead-us.com/topics/takakuwa-poster-99th-jps/): Dr. Takakuwa from the Pharmacology Business Unit, will deliver a poster presentation at The 99th Annual Meeting of the Japanese... - [Implementation of nonclinical C-QTc analysis: Demonstration of clinically relevant detection sensitivity with ICH E14/S7B Q&A](https://axcelead-us.com/posters/implementation-of-nonclinical-c-qtc-analysis-demonstration-of-clinically-relevant-detection-sensitivity-with-ich-e14-s7b-qa/): The 17th Annual Meeting of Japanese Safety Pharmacology Society Download - [Applicability of Ca transient measurements in cardiotoxicity screening](https://axcelead-us.com/posters/applicability-of-ca-transient-measurements-in-cardiotoxicity-screening/): The 17th Annual Meeting of Japanese Safety Pharmacology Society Download - [A paper by researcher Hitaka of the Pharmacology Business Unit has been published in the International Journal of Obesity.](https://axcelead-us.com/topics/hitaka-published-international-journal-of-obesity/): Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison Publication Published Date: 21... - [Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison](https://www.nature.com/articles/s41366-026-02025-2#new_tab): International Journal of Obesity - [Nissan Chemical and Axcelead DDP Enter into License Agreement for DNA-Encoded Library (DEL)](https://axcelead-us.com/news/nissan-chemical-license-agreement-for-del/): Tokyo and Fujisawa, Japan – February 24, 2026 – Nissan Chemical Corporation (Headquarter: Tokyo, Japan; Representative Director, President: Yagi Shinsuke;... - [A presentation at the CBI conference on exploring unexplored areas through omics analysis](https://axcelead-us.com/topics/a-presentation-at-the-cbi-conference/): Researcher Satomi from the DMPK & Safety Business Unit, will deliver an oral presentation at The 471st CBI Society Lecture... - [Researcher Tamura from DMPK & Safety Business Unit to Present a Poster at the 17th Annual Meeting of Japanese Safety Pharmacology Society](https://axcelead-us.com/topics/researcher-tamura-from-dmpk-safety-business-unit-to-present-a-poster-at-the-17th-annual-meating-of-japanese-safety-pharmacology-society/): Researcher Tamura from the DMPK & Safety Business Unit, will deliver a poster presentation at The 17th Annual Meeting of... - [Researcher Matsumoto from DMPK & Safety Business Unit to Present a Poster at the 17th Annual Meeting of Japanese Safety Pharmacology Society](https://axcelead-us.com/topics/matsumoto-japanese-safety-pharmacology-society/): Researcher Matsumoto from the DMPK & Safety Business Unit, will deliver a poster presentation at The 17th Annual Meeting of... - [SLAS2026 International Conference & Exhibition](https://axcelead-us.com/previous-conferences/slas2026/): Boston, MA - [Biotech Showcase 2026](https://axcelead-us.com/previous-conferences/biotech-showcase-2026/): San Francisco, CA - [Research article on advanced mass spectrometry analysis of disease-associated Asn-linked glycoconjugates in NGLY1 deficiency has been published](https://axcelead-us.com/topics/research-article-on-advanced-mass-spectrometry-analysis/): Structural characterization and insights into the formation of N-acetylglucosaminylasparagine and its derivatives in NGLY1-deficient models and patients Publication Published Date... - [Evaluation of γH2AX Assay for Screening Chromosomal Aberrations](https://axcelead-us.com/posters/evaluation-of-%ce%b3h2ax-assay-for-screening-chromosomal-aberrations/): The 54th Annual Meeting of JapaneseEnvironmental Mutagen and Genome Society (JEMS) Download - [Axcelead DDP Signs an Agreement with Astellas for HT-ADMET Studies](https://axcelead-us.com/news/axcelead-ddp-signs-an-agreement-with-astellas/): Fujisawa, Japan, December 11, 2025 – Axcelead Drug Discovery Partners, Inc. (President & CEO: Kengo Okada, Ph. D. ; hereinafter... - [Research Article on Exon Skipping in Alport Syndrome Mouse Model Published in Scientific Reports](https://axcelead-us.com/topics/research-article-on-exon-skipping-in-alport-syndrome-mouse-model/): Podocyte specific exon skipping after disease onset improves kidney pathology and function in a mouse model of Alport syndrome Publication... - [Podocyte specific exon skipping after disease onset improves kidney pathology and function in a mouse model of Alport syndrome](https://rdcu.be/eRJHG): Scientific Reports - [Research article on pharmacological evaluation using a MASH mouse model has been published in Scientific Reports](https://axcelead-us.com/topics/publication-in-scientific-reports/): Differences between Therapeutic Mechanisms of Resmetirom and Semaglutide against MASH in Western Diet-Fed MC4R-Knockout Mice Publication Published Date : November... - [DMPK Services](https://axcelead-us.com/brochures/dmpk-services/): Download - [Participation in the 16th Annual Conference on Biomolecular Screenology – Exhibition Booth and Corporate Seminar](https://axcelead-us.com/topics/participation-in-the-16th-cbs/): Conference Name: the 16th Conference on Biomolecular Screenology Axcelead will exhibit a corporate booth and host a seminar at the... - [Differences between Therapeutic Mechanisms of Resmetirom and Semaglutide against MASH in Western Diet-Fed MC4R-Knockout Mice](https://www.nature.com/articles/s41598-025-24927-3): Scientific Reports - [Researcher Shirai from DMPK BU to Deliver an Oral Presentation at the 16th Annual Conference on Biomolecular Screenology](https://axcelead-us.com/topics/shirai-oral-presentation-at-16thcbs/): Researcher Shirai from the DMPK Business Unit, will deliver a oral presentation at the 16th Annual Conference of Conference on... - [Researcher Yamasaki from DMPK BU to Present a Poster at the 16th Annual Conference on Biomolecular Screenology](https://axcelead-us.com/topics/yamasaki-to-present-a-poster-at-16thcbs/): Researcher Yamasaki from the DMPK Business Unit, will deliver a poster presentation at the 16th Annual Conference of Conference on... - [Anti-Obese Effects of GLP-1 Related Peptides on MC4R Deficient Mice and Nauseous Experiment Systems](https://axcelead-us.com/posters/anti-obese-effects-of-glp-1-related-peptides-on-mc4r-deficient-mice-and-nauseous-experiment-systems/): ObesityWeek® 2025 Download - [Development of drug metabolism method by human microbiome](https://axcelead-us.com/posters/development-of-drug-metabolism-method-by-human-microbiome/): The 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics Download - [DAR evaluation in mouse plasma using anti-human IgG immunocapture and intact mass spectrometry at the discovery stage](https://axcelead-us.com/posters/dar-evaluation-in-mouse-plasma-using-anti-human-igg-immunocapture-and-intact-mass-spectrometry-at-the-discovery-stage/): The 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics Download - [Axcelead DDP Enters into Contract Research Agreement with RealizeEdge Partners for the Creation of Candidate Compounds Targeting Specific Proteins](https://axcelead-us.com/news/contract-research-agreement-with-realizeedge-partners/): Fujisawa, Japan, November 11, 2025 – Axcelead Drug Discovery Partners, Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; Representative Director, President... - [Researcher Yoshida from Safety BU to Present a Poster at the 54th Annual Meeting of Japanese Environmental Mutagen and Genome Society (JEMS)](https://axcelead-us.com/topics/yoshida-to-present-a-poster-at-jems54th/): Researcher Yoshida from the Safety Business Unit, will deliver a poster presentation at the 54th Annual Meeting of the Japanese... - [Exhibiting at the 42nd Medicinal Chemistry Symposium](https://axcelead-us.com/topics/exhibiting-at-the-42nd-medicinal-chemistry-symposium/): Conference Name: the 42nd Medicinal Chemistry Symposium Date: November 18-20, 2025 (JST) Location: Awagin Hall (2-14 Aibacho, Tokushima City, Tokushima... - [Establishment of a TME-resembling in vitro assay system using freshly isolated human tumoroids](https://axcelead-us.com/posters/poster-tabata-jca8th/): The 84th Annual Meeting of the Japanese Cancer Association Download - [Immune Cell function and Effect of Immune Checkpoint Inhibitor in Freshly Dispersed Human Tumors](https://axcelead-us.com/posters/poster-unno-jca2025/): The 84th Annual Meeting of the Japanese Cancer Association Download - [BIO-Europe 2025](https://axcelead-us.com/previous-conferences/bio-europe-2025/): Vienna, Austria - [Dr. Nio from Pharmacology BU to Present a Poster at ObesityWeek® 2025](https://axcelead-us.com/topics/dr-nio-at-obesityweek-2025/): Dr. Yasunori Nio from the Pharmacology Business Unit, will deliver a poster presentation at ObesityWeek® 2025, to be held in... - [Exhibit at the 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics](https://axcelead-us.com/topics/exhibit-at-jssx40/): Conference Name: the 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics Date: October 20-23, 2025 (JST)... - [Maximizing Human Predictability from In Vivo Pharmacology Studies](https://axcelead-us.com/previous-seminars/in-vivo-pharmacology-studies/): Join this webinar to find out how we can help accelerate your Drug Discovery! our first speaker will provide an... - [NAMs Empower Translational Research](https://axcelead-us.com/previous-seminars/nams-empower-translational-research/): In April, the FDA announced that New Approach Methodologies (NAMs) will be encouraged to include in IND applications, while reducing... - [Researcher Kushal Rugjee from Screening BU to Present a Poster at ELRIG’s Drug Discovery 2025](https://axcelead-us.com/topics/researcher-kushal-rugjee-from-screening-bu-to-present-a-poster-at-elrigs-drug-discovery-2025/): Our researcher, Kushal Rugjee from the Screening Business Unit, will deliver an poster presentation at ELRIG’s Drug Discovery 2025, to... - [Pharmacology BU researcher Kusano will present at a symposium hosted by the Japan Association for Laboratory Animal Science](https://axcelead-us.com/topics/researcher-kusano-presentation-at-jalas/): Our researcher, Kaori Kusano from the Pharmacology Business Unit, will deliver an oral presentation at the Japan Association for Laboratory... - [Researcher Asano from DMPK BU to deliver Presentation about Spatial Transcriptomics at the 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics](https://axcelead-us.com/topics/researcher-asano-present-jssx40/): Our researcher, Shinya Asano from the DMPK Business Unit, will deliver an invited presentation about spatial transcriptomics at the 40th... - [Structural characterization and insights into the formation of N-acetylglucosaminylasparagine and its derivatives in NGLY1-deficient models and patients](https://rdcu.be/eRJHG): Glycobiology - [Researcher Nagasaka from DMPK BU to Present a Poster at the 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics](https://axcelead-us.com/topics/researcher-nagasaka-present-a-poster-jssx40/): Our researcher, Kosuke Nagasaka from the DMPK Business Unit, will present a poster at the 40th Annual Meeting of the... - [Researcher Nonaka from DMPK BU to Present a Poster at the 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics](https://axcelead-us.com/topics/researcher-nonaka-present-a-poster-jssx40/): Our researcher, Masami Nonaka from the DMPK Business Unit, will present a poster at the 40th Annual Meeting of the... - [Strategic Drug Discovery Support through Integrated Utilization of Preclinical Models to Enhance Human Clinical Translatability](https://axcelead-us.com/posters/strategic-drug-discovery-support-through-integrated-utilization-of-preclinical-models-to-enhance-human-clinical-translatability-2/): In-Vivo Science Symposium Download - [Strategic Drug Discovery Support through Integrated Utilization of Preclinical Models to Enhance Human Clinical Translatability](https://axcelead-us.com/presentations/strategic-drug-discovery-support-through-integrated-utilization-of-preclinical-models-to-enhance-human-clinical-translatability/): In-Vivo Science Symposium Download - [Axcelead DDP to Exhibit at Bio Japan 2025](https://axcelead-us.com/topics/bio-japan-2025/): Conference Name: Bio Japan 2025 Time: October 8-10, 2025 Venue: Pacifico Yokohama, Kanagawa, Japan Booth No. : D-27 Axcelead Drug... - [Dr. Kai from Safety BU to Deliver an Oral Presentation at the 9th Drug Discovery & Lead Optimization Conference](https://axcelead-us.com/topics/dr-kai-presentation-at-9th-drug-discovery-lead-optimization/): Dr. Kiyonori Kai from the Safety Business Unit, will deliver an oral presentation at The 9th Drug discovery & Lead... - [xFOREST Therapeutics and Axcelead DDP Launch Joint Research Initiative on RNA Structure-Targeted Small Molecule Drug Discovery](https://axcelead-us.com/news/xforest-axcelead-launch-joint-research/): Kyoto and Kanagawa, Japan, September 18, 2025 – xFOREST Therapeutics Co. , Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc.... - [Researcher Tanaka and Ogawa from Pharmacology BU to Present at a symposium hosted by CIEM](https://axcelead-us.com/topics/researcher-tanaka-and-ogawa-presentation-at-symposium/): Our researcher, Hiroshi Tanaka and Masahiro Ogawa from the Pharmacology Business Unit, will give an oral presentation at at a... - [Researcher Tabata from Pharmacology BU to Present a Poster at the 84th Annual Meeting of the Japanese Cancer Association](https://axcelead-us.com/topics/researcher-tabata-to-present-a-poster-at-japanese-cancer-association/): Our researcher, Ryotaro Tabata from the Pharmacology Business Unit, will present a poster at the 84th Annual Meeting of the... - [Researcher Unno from Pharmacology BU to Present a Poster at the 84th Annual Meeting of the Japanese Cancer Association](https://axcelead-us.com/topics/unno-to-present-a-poster-at-japanese-cancer-association/): Our researcher, Satoko Unno from the Pharmacology Business Unit, will present a poster at the 84th Annual Meeting of the... - [Axcelead Company Introduction](https://axcelead-us.com/brochures/axcelead-company-introduction/): Download - [Diverse Approaches to New Chemical Modalities -Challenging the Undruggable Targets beyond Conventional Small Molecule Drug Discovery-](https://axcelead-us.com/previous-seminars/new-chemical-modalities/): In recent years, targeted drug discovery has become increasingly challenging, making it essential to explore optimal modalities beyond traditional small... - [LSX USA Congress 2025](https://axcelead-us.com/previous-conferences/lsx-usa-2025/): Boston, MA - [Nissan Chemical and Axcelead DDP Enter into Business Partnership to Support Drug Discovery Research for RNA Therapeutics](https://axcelead-us.com/news/nissan-chemical/): Tokyo and Kanagawa, Japan, July 18, 2025 — Nissan Chemical Corporation (HQ: Tokyo, Japan; Representative Director, President and COO: Shinsuke... - [PRD Therapeutics Initiates First-in-Human Clinical Trial of SOAT2-Selective Inhibitor ‘PRD001’ — Axcelead DDP Provides Comprehensive Non-Clinical Development Support —](https://axcelead-us.com/topics/prd-therapeutics/): PRD Therapeutics, Inc. (“PRD Therapeutics”), a clinical stage company focused on developing novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia... - [Evaluation of oral exposure increase for poorly soluble compounds with dissolution-improving formulations](https://axcelead-us.com/posters/evaluation-of-oral-exposure-increase-for-poorly-soluble-compounds-with-dissolution-improving-formulations/): The 52nd Annual Meeting of the Japanese Society of Toxicology Download - [Lab-in-the-Loop Hit Discovery: Unlocking ‘Undruggable’ Targets with AI-Powered Hit Identification Platform](https://axcelead-us.com/previous-seminars/lab-in-the-loop-hit-discovery/): The discovery of lead compounds for classical druggable targets has become increasingly efficient; however, the development of therapeutics targeting “undruggable”... - [Development of an Exploratory Renal Toxicity Prediction Method for Oligonucleotide Therapeutics Using Human Proximal Tubule Epithelial Cells](https://axcelead-us.com/posters/development-of-an-exploratory-renal-toxicity-prediction-method-for-oligonucleotide-therapeutics-using-human-proximal-tubule-epithelial-cells/): The 10th Annual Meeting of the Nucleic Acids Therapeutics Society of Japan Download - [Researcher Oki from Screening BU to Deliver an Oral Presentation at the 52nd Annual Workshop of the Japanese Society of Toxicology](https://axcelead-us.com/topics/oki-presentation-japanese-society-of-toxicology/): Our researcher, Hideyuki Oki from the Screening Business Unit, will deliver an oral presentation at the 52nd Annual Meeting of... - [Researcher Hamada from DMPK BU to Present a Poster at the 52nd Annual Meeting of the Japanese Society of Toxicology](https://axcelead-us.com/topics/hamada-present-japanese-society-of-toxicology/): Our researcher, Teruki Hamada from the DMPK Business Unit, will present a poster at the 52nd Annual Meeting of the... - [Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship](https://axcelead-us.com/news/superluminal-collaborate-on-drug-discovery/): Kanagawa, Japan and Boston, MA, USA – Jun 23, 2025– Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead... # # Detailed Content ## Pages - Published: 2026-09-07 - Modified: 2026-09-07 - URL: https://axcelead-us.com/thank-you-inquiry-hts/ - Published: 2026-09-04 - Modified: 2026-09-07 - URL: https://axcelead-us.com/high-throughput-screening/ - Published: 2026-06-19 - Modified: 2026-06-19 - URL: https://axcelead-us.com/events/test-gateway/ - Published: 2026-06-19 - Modified: 2026-06-19 - URL: https://axcelead-us.com/webinar-gateway/ - Published: 2026-03-16 - Modified: 2026-04-06 - URL: https://axcelead-us.com/in-vitro-in-vivo-pharmacology/ - Published: 2025-12-08 - Modified: 2026-07-07 - URL: https://axcelead-us.com/integrated-drug-discovery/axcelead-booster/ - Published: 2025-08-08 - Modified: 2025-11-05 - URL: https://axcelead-us.com/ - Published: 2025-07-24 - Modified: 2026-04-06 - URL: https://axcelead-us.com/genetically-modified-animal/ - Published: 2025-06-09 - Modified: 2026-04-06 - URL: https://axcelead-us.com/bioinformatics/ - Published: 2025-05-21 - Modified: 2025-05-21 - URL: https://axcelead-us.com/topics/ - Published: 2025-05-21 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news-releases/ - Published: 2025-05-21 - Modified: 2026-04-06 - URL: https://axcelead-us.com/omics/ - Published: 2024-12-13 - Modified: 2026-04-06 - URL: https://axcelead-us.com/small-molecules/ > Axcelead Chemistry services are designed to help you create the medicines of the future. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive chemistry solutions can help you achieve your scientific goals more efficiently. - Published: 2024-12-13 - Modified: 2024-12-13 - URL: https://axcelead-us.com/chemistry/ - Published: 2024-11-14 - Modified: 2026-04-06 - URL: https://axcelead-us.com/targeted-protein-degraders/ - Published: 2024-11-14 - Modified: 2026-04-06 - URL: https://axcelead-us.com/rna-targeted-small-molecules/ - Published: 2024-08-08 - Modified: 2026-04-06 - URL: https://axcelead-us.com/peptide/ - Published: 2024-07-17 - Modified: 2026-04-06 - URL: https://axcelead-us.com/oligonucleotide/ - Published: 2024-05-08 - Modified: 2026-04-06 - URL: https://axcelead-us.com/therapeutic-areas/cardiovascular-metabolic-disease/ - Published: 2024-01-04 - Modified: 2024-01-04 - URL: https://axcelead-us.com/thank-you-inquiry/ > Welcome to view the conferences that Axcelead Drug Discovery Partners, Inc. has attended. - Published: 2023-12-19 - Modified: 2024-05-24 - URL: https://axcelead-us.com/events/previous-conferences/ - Published: 2023-12-13 - Modified: 2026-04-06 - URL: https://axcelead-us.com/integrated-drug-discovery/ind-enabling/ - Published: 2023-12-13 - Modified: 2026-04-06 - URL: https://axcelead-us.com/therapeutic-areas/neuroscience/ - Published: 2023-12-13 - Modified: 2026-04-06 - URL: https://axcelead-us.com/therapeutic-areas/immunology/ - Published: 2023-12-13 - Modified: 2026-04-06 - URL: https://axcelead-us.com/therapeutic-areas/oncology/ > Welcome to view the conferences that Axcelead Drug Discovery Partners, Inc. will be attending. - Published: 2023-12-09 - Modified: 2024-05-24 - URL: https://axcelead-us.com/events/conferences/ > Welcome to view the seminars that Axcelead Drug Discovery Partners, Inc. has held. - Published: 2023-12-09 - Modified: 2024-05-24 - URL: https://axcelead-us.com/events/previous-seminars/ > Welcome to view the seminars that Axcelead Drug Discovery Partners, Inc. will be holding. - Published: 2023-12-09 - Modified: 2024-05-24 - URL: https://axcelead-us.com/events/seminars/ - Published: 2023-12-09 - Modified: 2026-04-06 - URL: https://axcelead-us.com/integrated-drug-discovery/candidate-selection/ - Published: 2023-12-09 - Modified: 2026-04-06 - URL: https://axcelead-us.com/integrated-drug-discovery/lead-generation-optimization/ - Published: 2023-12-09 - Modified: 2026-04-06 - URL: https://axcelead-us.com/integrated-drug-discovery/hit-identification-characterization/ > Axcelead offers integrated drug discovery and development solutions to clients worldwide, including academia, biotechnology, and pharmaceutical companies. Our experienced team works closely with you at every step of your drug discovery project, from target identification, hit identification and characterization, lead generation and optimization, and candidate selection to IND enabling and beyond. - Published: 2023-12-09 - Modified: 2024-06-17 - URL: https://axcelead-us.com/integrated-drug-discovery/ - Published: 2023-12-09 - Modified: 2026-04-06 - URL: https://axcelead-us.com/integrated-drug-discovery/target-identification-validation/ - Published: 2023-12-04 - Modified: 2026-04-06 - URL: https://axcelead-us.com/contact-us/ - Published: 2023-11-30 - Modified: 2025-09-17 - URL: https://axcelead-us.com/resources/brochures/ - Published: 2023-11-30 - Modified: 2023-12-16 - URL: https://axcelead-us.com/resources/publications/ - Published: 2023-11-30 - Modified: 2024-06-05 - URL: https://axcelead-us.com/resources/presentations/ - Published: 2023-11-30 - Modified: 2026-08-20 - URL: https://axcelead-us.com/resources/videos/ - Published: 2023-11-30 - Modified: 2023-12-21 - URL: https://axcelead-us.com/resources/posters/ - Published: 2023-11-30 - Modified: 2024-01-04 - URL: https://axcelead-us.com/news/ - Published: 2023-11-29 - Modified: 2023-11-29 - URL: https://axcelead-us.com/test-page-with-mega-menu/ - Published: 2023-11-29 - Modified: 2024-01-04 - URL: https://axcelead-us.com/cookie-policy/ - Published: 2023-11-29 - Modified: 2023-12-16 - URL: https://axcelead-us.com/privacy-policy-personal-information-protection-policy/ - Published: 2023-11-16 - Modified: 2026-06-30 - URL: https://axcelead-us.com/about-us/ - Published: 2023-11-06 - Modified: 2024-01-04 - URL: https://axcelead-us.com/privacy-policy/ ## Posts - Published: 2026-09-09 - Modified: 2026-09-09 - URL: https://axcelead-us.com/future-seminars/webinar_20261015/ - Categories: Future Seminars Early-stage drug discovery is often hindered by two major challenges. The first is identifying initial hits against difficult-to-drug targets. The second is advancing HTS-derived hits into high-quality lead candidates. Many hits fail due to off-target activity, poor ADME-Tox profiles, limited SAR opportunities, or insufficient tractability for medicinal chemistry optimization. These limitations can slow project progression and reduce the likelihood of discovering differentiated candidates, highlighting the growing interest in innovative approaches to improve both hit identification and hit expansion. - Published: 2026-09-09 - Modified: 2026-09-09 - URL: https://axcelead-us.com/news/elix-and-addp-enter-into-collaborative-research-agreement/ - Categories: News, News Releases - Published: 2026-09-04 - Modified: 2026-09-07 - URL: https://axcelead-us.com/previous-seminars/fda-nams-road-map/ - Categories: Previous Seminars NAMs Road Map was published in April 2025. The goal in non-clinical safety studies is to transition from animal studies into NAMs within 3 to 5 years. FDA is accelerating validation and adoption of these methods, aiming to reduce animal use while improving predictive accuracy. However, pharmaceutical companies lack this information, and there are lots of uncertainties about what kinds of studies FDA will require when submitting IND/NDA files. In this video, we have delved deeper into unclear points with Dr. McGovern, a former FDA senior manager who had produced the NAMs Road Map. - Published: 2026-09-03 - Modified: 2026-09-08 - URL: https://axcelead-us.com/future-conferences/lsx-usa-congress-2026/ - Categories: Future Conferences Boston, MA - Published: 2026-08-27 - Modified: 2026-09-01 - URL: https://axcelead-us.com/topics/poster-presentation-at-safety-pharmacology-society-2026/ - Categories: Topics - Published: 2026-08-25 - Modified: 2026-08-25 - URL: https://axcelead-us.com/topics/job-shadowing-program/ - Categories: News, Topics - Published: 2026-07-31 - Modified: 2026-07-30 - URL: https://axcelead-us.com/topics/publication-in-chemmedchem/ - Categories: News, Topics - Published: 2026-07-28 - Modified: 2026-07-28 - URL: https://axcelead-us.com/future-seminars/webinar_20260910/ - Categories: Future Seminars Translational risk remains a major challenge in obesity and kidney disease drug development, often leading to uncertainty in preclinical decision-making. In obesity, the success of GLP-1 therapies has set a new benchmark, driving the development of both novel mechanisms beyond GLP-1 and combination strategies to address its limitations, including nausea, muscle loss, and weight regain. However, conventional preclinical evaluation based on body weight alone often fails to distinguish true pharmacological efficacy from adverse effect–driven outcomes. - Published: 2026-07-28 - Modified: 2026-09-01 - URL: https://axcelead-us.com/previous-seminars/webinar_20260825/ - Categories: Previous Seminars Translational risk remains a major challenge in oncology and immunology drug discovery. In oncology, the complexity of the tumor microenvironment and the growing diversity of therapeutic modalities—including antibody-drug conjugates (ADCs) and protein degraders—make it difficult to evaluate efficacy and predict clinical outcomes using conventional preclinical models. In immunology, disease heterogeneity and fundamental differences between rodent and human immune systems often limit confidence in target validation and candidate selection. - Published: 2026-07-22 - Modified: 2026-07-22 - URL: https://axcelead-us.com/news/notice-regarding-unauthorized-access-to-an-employee-email-account/ - Categories: News, News Releases - Published: 2026-07-07 - Modified: 2026-07-07 - URL: https://axcelead-us.com/topics/publication_acs-medicinal-chemistry-letters/ - Categories: News, Topics - Published: 2026-06-29 - Modified: 2026-06-26 - URL: https://axcelead-us.com/topics/dr-takakuwa-presentation-11th-natsj/ - Categories: Topics - Published: 2026-06-23 - Modified: 2026-06-22 - URL: https://axcelead-us.com/topics/hasegawa-present-poster-53rd-jsot/ - Categories: Topics - Published: 2026-06-19 - Modified: 2026-08-27 - URL: https://axcelead-us.com/test/maximizing-human-predictability-from-in-vivo-pharmacology-studies-2/ - Categories: Test Join this webinar to find out how we can help accelerate your Drug Discovery! our first speaker will provide an overview of these approaches, followed by a case study on anti-obesity drug development presented by our second speaker. - Published: 2026-06-19 - Modified: 2026-06-18 - URL: https://axcelead-us.com/topics/dr-liang-presentation-53rd-jsot/ - Categories: Topics - Published: 2026-06-18 - Modified: 2026-06-18 - URL: https://axcelead-us.com/news/addp-joins-lilly-tunelab/ - Categories: News, News Releases - Published: 2026-06-16 - Modified: 2026-06-15 - URL: https://axcelead-us.com/topics/furukawa-present-poster-53rd-jsot/ - Categories: Topics - Published: 2026-06-11 - Modified: 2026-08-28 - URL: https://axcelead-us.com/previous-seminars/webinar-cns-muscle_20260722/ - Categories: Previous Seminars Drug discovery for central nervous system (CNS) and muscle diseases continues to face major translational challenges. Conventional models often fail to capture human disease biology, while functional readouts can be difficult to reproduce, interpret, and translate into clinically meaningful outcomes. - Published: 2026-05-11 - Modified: 2026-08-28 - URL: https://axcelead-us.com/previous-seminars/improving-preclinical-decision-making-in-obesity-and-ckd-with-translational-in-vivo-phenotyping/ - Categories: Previous Seminars Join this webinar to find out how we can help you identify promising novel leads! In this webinar, we will showcase our integrated HTS platform and share our successful track record. We will also highlight the latest advances powered by computational chemistry and AI/ML technologies. - Published: 2026-05-11 - Modified: 2026-06-29 - URL: https://axcelead-us.com/previous-conferences/bio-international-convention-2026/ - Categories: Previous Conferences Boston, MA - Published: 2026-04-22 - Modified: 2026-04-22 - URL: https://axcelead-us.com/topics/j-pharmas-phase-1-clinical-trial-in-us/ - Categories: Topics - Published: 2026-04-09 - Modified: 2026-04-09 - URL: https://axcelead-us.com/topics/co-authored-paper-published-in-gut-pathogens/ - Categories: News, Topics - Published: 2026-03-24 - Modified: 2026-06-11 - URL: https://axcelead-us.com/topics/yamamoto-present-poster-wcn2026/ - Categories: Topics - Published: 2026-03-18 - Modified: 2026-03-24 - URL: https://axcelead-us.com/topics/hashikami-present-poster-wcn2026/ - Categories: Topics - Published: 2026-03-16 - Modified: 2026-03-16 - URL: https://axcelead-us.com/news/proteros-addp-strategic-collaboration/ - Categories: News, News Releases - Published: 2026-03-09 - Modified: 2026-04-02 - URL: https://axcelead-us.com/topics/miura-publication-metabolites/ - Categories: News, Topics - Published: 2026-03-09 - Modified: 2026-03-09 - URL: https://axcelead-us.com/topics/hirano-present-99th-jps/ - Categories: Topics - Published: 2026-03-09 - Modified: 2026-03-08 - URL: https://axcelead-us.com/topics/hitaka-poster-99th-jps/ - Categories: Topics - Published: 2026-03-09 - Modified: 2026-03-08 - URL: https://axcelead-us.com/topics/murakami-symposium-99th-jps/ - Categories: Topics - Published: 2026-03-09 - Modified: 2026-03-08 - URL: https://axcelead-us.com/topics/takakuwa-poster-99th-jps/ - Categories: Topics - Published: 2026-02-25 - Modified: 2026-02-24 - URL: https://axcelead-us.com/topics/hitaka-published-international-journal-of-obesity/ - Categories: News, Topics - Published: 2026-02-24 - Modified: 2026-02-23 - URL: https://axcelead-us.com/news/nissan-chemical-license-agreement-for-del/ - Categories: News, News Releases - Published: 2026-02-20 - Modified: 2026-02-19 - URL: https://axcelead-us.com/topics/a-presentation-at-the-cbi-conference/ - Categories: Topics - Published: 2026-02-17 - Modified: 2026-02-17 - URL: https://axcelead-us.com/topics/researcher-tamura-from-dmpk-safety-business-unit-to-present-a-poster-at-the-17th-annual-meating-of-japanese-safety-pharmacology-society/ - Categories: Topics - Published: 2026-02-17 - Modified: 2026-02-17 - URL: https://axcelead-us.com/topics/matsumoto-japanese-safety-pharmacology-society/ - Categories: Topics - Published: 2026-01-13 - Modified: 2026-02-19 - URL: https://axcelead-us.com/previous-conferences/slas2026/ - Categories: Previous Conferences Boston, MA - Published: 2025-12-22 - Modified: 2026-01-20 - URL: https://axcelead-us.com/previous-conferences/biotech-showcase-2026/ - Categories: Previous Conferences San Francisco, CA - Published: 2025-12-17 - Modified: 2025-12-17 - URL: https://axcelead-us.com/topics/research-article-on-advanced-mass-spectrometry-analysis/ - Categories: News, Topics - Published: 2025-12-11 - Modified: 2025-12-10 - URL: https://axcelead-us.com/news/axcelead-ddp-signs-an-agreement-with-astellas/ - Categories: News, News Releases - Published: 2025-12-05 - Modified: 2025-12-04 - URL: https://axcelead-us.com/topics/research-article-on-exon-skipping-in-alport-syndrome-mouse-model/ - Categories: News, Topics - Published: 2025-11-21 - Modified: 2025-12-01 - URL: https://axcelead-us.com/topics/publication-in-scientific-reports/ - Categories: News, Topics - Published: 2025-11-20 - Modified: 2025-11-19 - URL: https://axcelead-us.com/topics/participation-in-the-16th-cbs/ - Categories: Topics - Published: 2025-11-18 - Modified: 2025-11-20 - URL: https://axcelead-us.com/topics/shirai-oral-presentation-at-16thcbs/ - Categories: Topics - Published: 2025-11-18 - Modified: 2025-11-27 - URL: https://axcelead-us.com/topics/yamasaki-to-present-a-poster-at-16thcbs/ - Categories: Topics - Published: 2025-11-11 - Modified: 2025-11-11 - URL: https://axcelead-us.com/news/contract-research-agreement-with-realizeedge-partners/ - Categories: News, News Releases - Published: 2025-11-11 - Modified: 2025-11-11 - URL: https://axcelead-us.com/topics/yoshida-to-present-a-poster-at-jems54th/ - Categories: Topics - Published: 2025-11-10 - Modified: 2025-11-10 - URL: https://axcelead-us.com/topics/exhibiting-at-the-42nd-medicinal-chemistry-symposium/ - Categories: Topics - Published: 2025-10-29 - Modified: 2025-11-12 - URL: https://axcelead-us.com/previous-conferences/bio-europe-2025/ - Categories: Previous Conferences Vienna, Austria - Published: 2025-10-24 - Modified: 2025-10-27 - URL: https://axcelead-us.com/topics/dr-nio-at-obesityweek-2025/ - Categories: Topics - Published: 2025-10-20 - Modified: 2025-10-20 - URL: https://axcelead-us.com/topics/exhibit-at-jssx40/ - Categories: Topics - Published: 2025-10-20 - Modified: 2026-08-28 - URL: https://axcelead-us.com/previous-seminars/in-vivo-pharmacology-studies/ - Categories: Previous Seminars Join this webinar to find out how we can help accelerate your Drug Discovery! our first speaker will provide an overview of these approaches, followed by a case study on anti-obesity drug development presented by our second speaker. - Published: 2025-10-19 - Modified: 2026-08-28 - URL: https://axcelead-us.com/previous-seminars/nams-empower-translational-research/ - Categories: Previous Seminars In April, the FDA announced that New Approach Methodologies (NAMs) will be encouraged to include in IND applications, while reducing the animal testing requirements. This webinar will provide three key technologies relevant to NAMs. These technologies can be introduced prior to IND or clinical studies. - Published: 2025-10-17 - Modified: 2025-10-17 - URL: https://axcelead-us.com/topics/researcher-kushal-rugjee-from-screening-bu-to-present-a-poster-at-elrigs-drug-discovery-2025/ - Categories: Topics - Published: 2025-10-17 - Modified: 2025-10-17 - URL: https://axcelead-us.com/topics/researcher-kusano-presentation-at-jalas/ - Categories: Topics - Published: 2025-10-17 - Modified: 2025-10-17 - URL: https://axcelead-us.com/topics/researcher-asano-present-jssx40/ - Categories: Topics - Published: 2025-10-09 - Modified: 2025-10-08 - URL: https://axcelead-us.com/topics/researcher-nagasaka-present-a-poster-jssx40/ - Categories: Topics - Published: 2025-10-07 - Modified: 2025-10-06 - URL: https://axcelead-us.com/topics/researcher-nonaka-present-a-poster-jssx40/ - Categories: Topics - Published: 2025-09-19 - Modified: 2025-09-19 - URL: https://axcelead-us.com/topics/bio-japan-2025/ - Categories: Topics - Published: 2025-09-18 - Modified: 2025-09-18 - URL: https://axcelead-us.com/topics/dr-kai-presentation-at-9th-drug-discovery-lead-optimization/ - Categories: Topics - Published: 2025-09-18 - Modified: 2025-09-18 - URL: https://axcelead-us.com/news/xforest-axcelead-launch-joint-research/ - Categories: News, News Releases - Published: 2025-09-11 - Modified: 2025-09-11 - URL: https://axcelead-us.com/topics/researcher-tanaka-and-ogawa-presentation-at-symposium/ - Categories: Topics - Published: 2025-09-09 - Modified: 2025-09-09 - URL: https://axcelead-us.com/topics/researcher-tabata-to-present-a-poster-at-japanese-cancer-association/ - Categories: Topics - Published: 2025-09-04 - Modified: 2025-09-04 - URL: https://axcelead-us.com/topics/unno-to-present-a-poster-at-japanese-cancer-association/ - Categories: Topics - Published: 2025-08-22 - Modified: 2026-08-28 - URL: https://axcelead-us.com/previous-seminars/new-chemical-modalities/ - Categories: Previous Seminars In recent years, targeted drug discovery has become increasingly challenging, making it essential to explore optimal modalities beyond traditional small molecules to develop new drugs successfully. - Published: 2025-08-05 - Modified: 2025-10-02 - URL: https://axcelead-us.com/previous-conferences/lsx-usa-2025/ - Categories: Previous Conferences Boston, MA - Published: 2025-07-18 - Modified: 2025-07-18 - URL: https://axcelead-us.com/news/nissan-chemical/ - Categories: News, News Releases - Published: 2025-07-15 - Modified: 2025-07-15 - URL: https://axcelead-us.com/topics/prd-therapeutics/ - Categories: Topics - Published: 2025-07-11 - Modified: 2026-08-28 - URL: https://axcelead-us.com/previous-seminars/lab-in-the-loop-hit-discovery/ - Categories: Previous Seminars The discovery of lead compounds for classical druggable targets has become increasingly efficient; however, the development of therapeutics targeting “undruggable” targets continues to face significant hurdles and unmet needs. One of the key challenges in the hit-finding stage is the difficulty in identifying initial hits and obtaining seed compounds that can serve as viable starting points for lead optimization. - Published: 2025-06-30 - Modified: 2025-06-30 - URL: https://axcelead-us.com/topics/oki-presentation-japanese-society-of-toxicology/ - Categories: Topics - Published: 2025-06-24 - Modified: 2025-06-24 - URL: https://axcelead-us.com/topics/hamada-present-japanese-society-of-toxicology/ - Categories: Topics - Published: 2025-06-23 - Modified: 2025-06-24 - URL: https://axcelead-us.com/news/superluminal-collaborate-on-drug-discovery/ - Categories: News, News Releases - Published: 2025-06-23 - Modified: 2025-06-23 - URL: https://axcelead-us.com/topics/dr-fukui-presentation-at-japanese-society-of-toxicology/ - Categories: Topics - Published: 2025-06-20 - Modified: 2025-06-23 - URL: https://axcelead-us.com/topics/poster_presentation-at-the-japan-nucleic-acid-therapeutics-society/ - Categories: Topics - Published: 2025-06-17 - Modified: 2025-06-16 - URL: https://axcelead-us.com/news/sign-3-way-mou-to-develop-adc-toolbox/ - Categories: News, News Releases - Published: 2025-06-10 - Modified: 2025-06-23 - URL: https://axcelead-us.com/topics/the-structure-activity-forum-2025/ - Categories: Topics - Published: 2025-05-21 - Modified: 2025-06-23 - URL: https://axcelead-us.com/previous-conferences/bio-international-convention-2025/ - Categories: Previous Conferences Boston, MA - Published: 2025-04-25 - Modified: 2025-06-24 - URL: https://axcelead-us.com/topics/the-results-of-joint-research-with-luxna-biotec-inc-published-in-nucleic-acid-therapeutics/ - Categories: News, Topics - Published: 2025-04-24 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/easl-congress-2025/ - Categories: Previous Conferences Amsterdam, the Netherlands - Published: 2025-04-23 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/eco2025/ - Categories: Previous Conferences Malaga, Spain - Published: 2025-04-21 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/bio-korea-2025/ - Categories: Previous Conferences COEX, Seoul, Korea - Published: 2025-04-08 - Modified: 2025-06-24 - URL: https://axcelead-us.com/topics/research-article-co-authored-on-ferroptosis-moa-analysis-published-in-communications-biology/ - Categories: Topics - Published: 2025-03-25 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/drug-discovery-chemistry-2025/ - Categories: Previous Conferences San Diego, CA - Published: 2025-02-20 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/bio-europe-spring-2025/ - Categories: Previous Conferences Milan, Italy - Published: 2025-02-12 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/global-life-science-partnering-%ef%bc%86investor-conference-2025/ - Categories: Previous Conferences San Diego, CA - Published: 2025-01-15 - Modified: 2026-08-28 - URL: https://axcelead-us.com/previous-seminars/accelerate-targeted-protein-degradation-drug-discovery-with-axceleads-integrated-platform-deglead/ - Categories: Previous Seminars Targeted Protein Degradation (TPD), including bifunctional degraders and molecular glue degraders, represents a paradigm shift in small molecule drug discovery. However, challenges remain in successfully discovering new TPD drugs. For example, bifunctional degraders face issues such as unfavorable ADME and physicochemical properties due to their molecular complexity. Regarding molecular glue degraders, the discovery of promising compounds often relies heavily on serendipity. - Published: 2024-12-26 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/20241226-e-newsrelease/ - Categories: News, News Releases - Published: 2024-12-13 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/slas2025-international-conference-exhibition/ - Categories: Previous Conferences San Diego, CA - Published: 2024-11-05 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/the-liver-meeting-tlm-2024/ - Categories: Previous Conferences San Diego, CA - Published: 2024-10-31 - Modified: 2026-08-28 - URL: https://axcelead-us.com/previous-seminars/axceleads-integrated-hts-platform-powered-by-computational-chemistry-and-ai-ml/ - Categories: Previous Seminars High Throughput Screening (HTS) is one of the most powerful tools in small molecule drug discovery for identifying promising novel leads. The success of HTS depends on the design of an appropriate screening flow, the development of robust assay systems, and the availability of a high-quality compound library. - Published: 2024-10-31 - Modified: 2025-06-24 - URL: https://axcelead-us.com/news/research-results-of-a-mouse-model-of-chronic-kidney-disease-axcc-mice-generated-in-axcelead-ddp-has-been-published-in-the-american-journal-of-pathology-as-a-co-authored-article/ - Categories: News, Topics - Published: 2024-10-21 - Modified: 2025-06-24 - URL: https://axcelead-us.com/news/a-co-authored-paper-regarding-immunocompromised-type-1-diabetic-mini-pigs-was-published-in-the-cell-transplantation/ - Categories: News, Topics - Published: 2024-09-27 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/bio-europe-2024/ - Categories: Previous Conferences Stockholm, Sweden - Published: 2024-09-10 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-drug-discovery-partners-enters-into-master-service-agreement-for-drug-discovery-projects-with-acadia-pharmaceuticals/ - Categories: News, News Releases - Published: 2024-09-05 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddp-and-lilly-enter-into-research-and-collaboration-agreement/ - Categories: News, News Releases - Published: 2024-07-25 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/neuroscience-2024/ - Categories: Previous Conferences Chicago, IL - Published: 2024-05-29 - Modified: 2025-06-24 - URL: https://axcelead-us.com/news/axcelead-ddp-has-become-a-certified-provider-of-single-cell-gene-expression-solution-from-10x-genomics/ - Categories: News, Topics - Published: 2024-05-27 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/achieved-the-first-milestone-in-drug-discovery-support-to-otsuka-pharmaceutical/ - Categories: News, News Releases - Published: 2024-05-08 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/bio-international-convention-2024/ - Categories: Previous Conferences San Diego, CA - Published: 2024-04-01 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/change-of-representative-director/ - Categories: News, News Releases - Published: 2024-02-29 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/aacr-annual-meeting-2024/ - Categories: Previous Conferences San Diego, CA - Published: 2024-02-14 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/global-life-science-partnering-%ef%bc%86investor-conference/ - Categories: Previous Conferences San Diego, CA